Perspective Therapeutics (NYSEAMERICAN:CATX) CEO Johan Spoor Buys 47,000 Shares of Company Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) CEO Johan Spoor bought 47,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The stock was bought at an average price of $0.81 per share, for a total transaction of $38,070.00. Following the completion of the acquisition, the chief executive officer directly owned 106,383 shares in the company, valued at approximately $86,170.23. The trade was a 79.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $0.84 on Friday. The stock’s fifty day moving average is $2.15 and its 200-day moving average is $3.45. The company has a quick ratio of 6.61, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. Perspective Therapeutics, Inc. has a 12-month low of $0.78 and a 12-month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. Equities research analysts predict that Perspective Therapeutics, Inc. will post -1.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Royal Bank Of Canada lowered shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $14.00 to $4.00 in a research note on Monday, October 26th. William Blair assumed coverage on shares of Perspective Therapeutics in a research report on Friday, September 18th. They issued an “outperform” rating on the stock. Piper Sandler cut their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. BMO Capital Markets restated an “outperform” rating on shares of Perspective Therapeutics in a report on Friday, October 30th. Finally, Bank of America reduced their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.10.

Read Our Latest Research Report on CATX

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CATX. Provenance Wealth Advisors LLC acquired a new stake in Perspective Therapeutics during the third quarter valued at $44,000. Auctus Advisors LLC increased its position in Perspective Therapeutics by 83.6% in the 3rd quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock worth $103,000 after purchasing an additional 17,015 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Perspective Therapeutics by 53.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock worth $168,000 after purchasing an additional 21,150 shares in the last quarter. Taylor & Morgan Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 127.6% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock worth $225,000 after purchasing an additional 37,000 shares in the last quarter. Finally, Quantinno Capital Management LP purchased a new stake in shares of Perspective Therapeutics during the 1st quarter worth about $273,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Read More

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.